Latest KRAS Stories
The pattern of genomic alterations in colon and rectal tissues is the same regardless of anatomic location or origin within the colon or the rectum, leading researchers to conclude that these two cancer types can be grouped as one.
Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.
A pair of recent studies describes how pancreatic cancer cells produce a protein that attracts the body's immune cells and tricks them into helping cancer cells grow.
A genetic mutation that drives the initiation of pancreatic cancer also manipulates metabolic pathways to support tumor growth and progression.
When combined with other treatments, the drug cetuximab—which works by slowing or stopping the growth of cancer cells—has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers.